Anika Therapeutics Inc (NAS:ANIK)
$ 16.9601 0.6601 (4.05%) Market Cap: 248.39 Mil Enterprise Value: 201.25 Mil PE Ratio: 0 PB Ratio: 1.39 GF Score: 80/100

Q2 2020 Anika Therapeutics Inc Earnings Call Transcript

Jul 30, 2020 / 09:00PM GMT
Release Date Price: $37.17 (+2.45%)
Operator

Welcome to the Q2 2020 Anika Therapeutics Earnings Conference Call. (Operator Instructions) and the conference is being recorded. (Operator Instructions) I would now like to turn the conference over to Kristen Galfetti, Executive Director of Investor Relations. Please go ahead, ma'am.

Kristen Galfetti;Executive Director of Investor Relations

Thank you, Carl. Good evening, everyone. And thank you for joining us. With me today on the call is Dr. Cheryl Blanchard, President and Chief Executive Officer; and Sylvia Cheung, Chief Financial Officer of Anika.

During today's call, Cheryl and Sylvia will review Anika's second quarter 2020 financial results and key business highlights, which were summarized in our earnings release today. A copy of the earnings release is available on the Investor Relations section of our website at anikatherapeutics.com. In addition, a slide presentation is posted on our website in the Investor Relations section under the Events and Presentations tab. We invite you to take a moment now to open the file and follow the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot